Enhanced Liver Fibrosis (ELF™) Blood Test to assess prognosis in patients

Disclaimer: The products/features (mentioned herein) are not commercially available in all countries. Their future availability cannot be guaranteed.

In the U.S., the ELF Test is indicated as a prognostic marker in conjunction with other laboratory findings and clinical assessments in patients with advanced fibrosis (F3 or F4) due to non-alcoholic steatohepatitis (NASH) to assess the likelihood of progression to cirrhosis and liver-related clinical events. The test is not for use in the diagnosis of NASH or for the staging of fibrosis. Please contact Siemens Healthineers directly for availability.

The Enhanced Liver Fibrosis (ELF^TM) Test is a non-invasive blood test that measures three analytes linked to liver fibrosis. The ELF Test is a simple, efficient blood test for determining prognosis in individuals with advanced fibrosis (F3 or F4) caused by non-alcoholic steatohepatitis (NASH), a kind of non-alcoholic fatty liver disease (NAFLD) characterized by liver inflammation.

The ELF score can be used by clinicians to determine the chance of cirrhosis as well as other liver-related clinical problems.

ELF Test benefits

The ELF Test has been thoroughly investigated and evaluates active, dynamic fibrosis instead of the destruction it has already produced. As a result, the ELF Test can be utilized as a prognostic indicator.

The ELF Test simplifies and speeds the identification of NASH patients with severe fibrosis who could profit most from potentially life-saving preventative therapy, a critical first step in reversing the tide against the silent killer of the liver.

• Improve patient management by stratifying advanced NASH patients who are more likely to develop cirrhosis and LREs.
• Improve patient care using a blood test that allows for more frequent prognostic evaluations.
• All patients, even those with type 2 diabetes and obesity, may get noninvasive testing with a simple blood test.

1. Sanyal AJ, et al. Hepatology. 2019;70(6): 1913–1927
2. Patel P, et al. Hepatol Commun. 2018;2:893-905.
3. Karlas T, et al. PLoS ONE. 2015;10(11):e0141649.